My Top 3 Drug Stocks for March 2026
2026-03-20 06:50:00 ET
Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in this industry is that there will always be a need for innovative medicines, which remain in high demand regardless of economic conditions. That makes drugmakers, particularly the best ones capable of consistently developing new products, attractive long-term holdings. Let's consider three, in particular, that look attractive right now: Eli Lilly (NYSE: LLY) , Vertex Pharmaceuticals (NASDAQ: VRTX) , and Pfizer (NYSE: PFE) .
Image source: Getty Images.
The market for chronic weight management drugs has taken off in recent years. Analysts predict it will continue to expand over the next decade. No drugmaker is better positioned to capitalize on this than Eli Lilly. The company already leads this market thanks to tirzepatide, a compound approved for diabetes, weight loss, and obstructive sleep apnea in obese patients. Tirzepatide is beating records.
NASDAQ: VRTX
VRTX Trading
1.0% G/L:
$456.04 Last:
585,474 Volume:
$454.62 Open:
